Acetylsalicylic acid in primary and secondary prevention of cardiovascular diseases. Is it all obvious?
https://doi.org/10.21518/2079-701X-2015-12-66-71
Abstract
The review tells about the results of clinical trials and meta-analyses demonstrating the effectiveness of acetylsalicylic acid (ASA) for secondary prevention of cardiovascular diseases, namely, improved prognosis for patients after myocardial infarction (MI), stroke or transient ischemic attack (TIA), people currently having AMI, stroke and stable CAD. Risk reduction is most significant for non-fatal events, and less significant for cardiovascular mortality. However, indications for use of ASA in patients without established cardiovascular disease remain a subject for debate today, as interpretation of the available data on ASA effect in primary prevention is quite complicated, while long-term administration is associated with a risk of hemorrhagic complications. Guidelines of the Working Group on Thrombosis of the European Society of Cardiology and the American Diabetes Association are presented, where the use of ASA for primary prevention is justified only in patients with high cardiovascular risk. Safety issues in the ASA treatment and options for prevention of gastrointestinal bleeding are also discussed.
About the Authors
A. V. Panov
V.A. Almazov Federal North-West Medical Research Centre
Russian Federation
Russian Federation
E. V. Kuleshova
V.A. Almazov Federal North-West Medical Research Centre
Russian Federation
Russian Federation
References
1. Vane JR Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drug. Nature (New Biol) 1971; 231: 232-235.
2. Smith JH, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biol) 1971; 231: 235-237
3. Antiplatelet Trialists Collaboration. Collaborative overview of randomized of antiplatelet therapy: I Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet in various categories of patients. BMJ 1994; 308: 81-106.
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. Jan 12 2002; 324: 71-86.
5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 2: 349-360.
6. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
7. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992; 340: 1421-1425.
8. Collaborative overview of randomized trials of antiplatelet therapy: I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
9. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124: 2458-2473.
10. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the Fif th Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol. 2012; 19(4): 585-667.
11. Secondary prevention for patients after a myo-cardial infarction: summary of updated NICE guidance BMJ 2013; 347: f6544.
12. Vandvik PO , Lincoff AM, Gore JM. et al. Primary and Secondary Prevention of Cardiovascular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl (2suppl): 48S-52S.
13. ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
14. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-6.
15. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
16. Primary Prevention Project Investigators. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95.
17. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
18. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
19. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
20. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107: 1796-801.
21. Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011; 124: 621-9.
22. Berger JS, Lala A, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 2011; 162: 115-24, e2.
23. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascu-lar outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-16.
24. Ikeda Y, Shimada K, Teramoto T, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Аtherosclerotic Risk Factors: A Randomized Clinical Trial. JAMA. 2014; 312: 2510-2520.
25. Jones WS, Schmit KM, Vemulapalli S, et al. Treatment Strategies for Patients With Peripheral Artery Disease. Rockville, MD: 2013.
26. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321(3): 129-35.
27. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13): 1293-304.
28. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404.
29. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease.
30. Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-701.
31. Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin Therapy in Primary Cardiovascular Disease Prevention. A Position Paper of the European Society of Cardiology Working Group on Thrombosis JACC 2014; 6 4: 319-327.
32. Matthys F, De Backer T, De Backer G, Vander Stichele R. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker? European Journal of Preventive Cardiology 2014, Vol. 21(3) 354-365.
33. Robertson L, Atallah E, Stansby G. Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneu-rysm. Cochrane Database Syst Rev 2014; 1: CD010447.
34. US Food and Drug Administration. Use of aspirin for primary prevention of heart attack and stroke. May 2, 2014.
35. Patrono С. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? Eur Heart Journal (2013) 34, 34033411.
36. RydeTn L, Grant PJ. Anker SD. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD ( The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart Journ (2013) 34, 3035-3087
Review
For citations:
Panov AV, Kuleshova EV. Acetylsalicylic acid in primary and secondary prevention of cardiovascular diseases. Is it all obvious? Meditsinskiy sovet = Medical Council. 2015;(12):66-71. (In Russ.) https://doi.org/10.21518/2079-701X-2015-12-66-71
Views:
432
Email this article 